Cell and Gene Therapy Insights Volume 9 Issue 3

Volume 9 Issue 3

Download PDF

Featuring

Issue Spotlight: Vector bioprocessing & raw materials
Other articles
Webinars

Vector bioprocessing & raw materials

Innovator Insight

Determination of physical viral vector titer in process development & QC for cell & gene therapy

Daniel Forsström, John Chappell

4 May 2023

Read

Sustainable plasmid DNA strategies, achieving streamlined secure supply to clinic & commercialization

Andrew Frazer, Amanda Weiss

26 April 2023

Read

Expert Roundtable

Driving the expansion of mRNA into the therapeutic sphere

Alejandro Becerra, Andreas Kuhn, Metin Kurtoglu

10 April 2023

Read

Commentary

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

G Thakur, S Mink, H Bak et al.

6 June 2023

Read

Infographic

Plasmid DNA manufacturing and analytics: INFOGRAPHIC

29 July 2023

Read

Viewpoint

Standardizing success: paving the way for streamlined viral vector manufacturing in gene therapy

Raquel Martín-Ibáñez

26 April 2023

Read

Setting up a one-stop shop: bringing viral vector manufacturing in-house

Danielle Steele

17 April 2023

Read

Transfection optimization for AAV production

Peter Boyce

3 April 2023

Read

Interview

Exploring the evolution of upstream & downstream viral vector processing

Francesca Vitelli

3 April 2023

Read

articles

Innovator Insight

Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform

Issa Jyamubandi

1 April 2023

Read

Expert Roundtable

Accelerating cancer therapies development: the importance of platform, process, and partnership

William Swaney, John (Yoshi) Shyu, Nikhil Tyagi

22 April 2023

Read

FastFacts

Advancing AAV gene therapy development for the treatment of neurodegenerative diseases

Carina Peritore

21 April 2023

Read

Viewpoint

Funding the future: cell & gene therapy development

Nick Meyers, Neil Fish

28 March 2023

Read

Interview

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Pim Hermans, Frank Detmers

7 March 2023

Watch

Case studies: Successful scale-up of upstream viral vector processes using adherent and suspension platforms

Samir Acharya, Denis Kole

14 March 2023

Watch

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Y Zhi, C Le Bec, M Brewer et al.

22 March 2023

Watch

Scalable production in single-use bioreactors

Jonathan Zmuda PhD, Premkumar Jayaraman PhD

29 March 2023

Watch

Chromatographic modalities, buffer selection and other considerations for enrichment of AAV product

Rok Žigon

5 April 2023

Watch

De-risking lentiviral vector production using a robust, scalable, suspension-based platform

Jimmy Xin, Poornima Manavalan

11 April 2023

Watch

Skip the hassle for AAV and AdV empty/full and titer data with Stunner

Nelis Denys

12 April 2023

Watch

Development of anti-AAV assay for detection of pre-existing AAV immunity

Zhe Liu, John Chappell

18 April 2023

Watch

Analyzing full and empty AAV capsid ratio in less than 5 minutes

Åsa Hagner-McWhirter PhD

19 April 2023

Watch

Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells

Deepak Kumar

20 April 2023

Watch

High-throughput process & analytical platforms to accelerate gene therapy scale-up

P Starremans PhD, K Warrington PhD, N Jesuraj PhD

25 April 2023

Watch

Environmental monitoring: optimizing microbial control in cell and gene therapy workflows

Nico Chow

27 April 2023

Watch

Manufacturing and testing a clinical-grade AAV vector: from concept to clinic

Chris Edwards, James Cody

4 May 2023

Watch

Future-proof your AAV process with a complete producer cell line – just induce and grow

Dovile Gruzdyte

25 May 2023

Watch

CELL AND GENE THERAPY INSIGHTS

April 2023 Issue

Volume 9 Issue 3

Featuring

SPOTLIGHT

Vector bioprocessing & raw materials

Innovator Insight

Determination of physical viral vector titer in process development & QC for cell & gene therapy

Sustainable plasmid DNA strategies, achieving streamlined secure supply to clinic & commercialization

Expert Roundtable

Driving the expansion of mRNA into the therapeutic sphere

Commentary

Opportunities to implement continuous processing in production of recombinant adeno-associated viral vectors

Infographic

Plasmid DNA manufacturing and analytics: INFOGRAPHIC

Viewpoint

Standardizing success: paving the way for streamlined viral vector manufacturing in gene therapy

Setting up a one-stop shop: bringing viral vector manufacturing in-house

Transfection optimization for AAV production

Interview

Exploring the evolution of upstream & downstream viral vector processing

articles

Innovator Insight

Challenges of developing anti-drug antibody & concentration (PK or PD) assays for liposomal transgene enzymes on an automated immunoassay platform

Expert Roundtable

Accelerating cancer therapies development: the importance of platform, process, and partnership

FastFacts

Advancing AAV gene therapy development for the treatment of neurodegenerative diseases

Viewpoint

Funding the future: cell & gene therapy development

Interview

A payment innovation framework to meet the urgent need in advanced therapies

Key considerations & development of regulatory guidance in CMC

New directions and evolving challenges in the CAR-T cell therapy space

Webinars

The fast and the curious – optimized development of high performing AAV vectors

Advancing the purification of VSV-G pseudotyped lentiviral vectors by using affinity chromatography

Case studies: Successful scale-up of upstream viral vector processes using adherent and suspension platforms

Navigating evolving regulatory CMC guidance in the AAV gene therapy field

Scalable production in single-use bioreactors

Chromatographic modalities, buffer selection and other considerations for enrichment of AAV product

De-risking lentiviral vector production using a robust, scalable, suspension-based platform

Skip the hassle for AAV and AdV empty/full and titer data with Stunner

Development of anti-AAV assay for detection of pre-existing AAV immunity

Analyzing full and empty AAV capsid ratio in less than 5 minutes

Large-scale genome editing of primary human natural killer (NK) cells: A quest toward manufacture of clinically relevant CAR NK cells

High-throughput process & analytical platforms to accelerate gene therapy scale-up

Environmental monitoring: optimizing microbial control in cell and gene therapy workflows

Manufacturing and testing a clinical-grade AAV vector: from concept to clinic

Future-proof your AAV process with a complete producer cell line – just induce and grow